Integrated Biopharma, Inc. Announces Change in Record Date

HILLSIDE, N.J., July 31, 2008 (PRIME NEWSWIRE) -- Integrated Biopharma, Inc.
(Nasdaq:INBP) today announced that it has changed its record date to August 12,
2008 from August 4, 2008 for the spin-off of the Company's interest in
iBioPharma, Inc. (formerly InB:Biotechnologies, Inc.) ("iBioPharma") as
announced on July 25, 2008.

The shares will be distributed, in book-entry form, effective as of 11:59 p.m.
on August 18, 2008 (the "Distribution Date"). For each share of the Company's
common stock that a stockholder owns as of the end of August 12, 2008 (the
"Record Date"), such stockholder is entitled to receive one share of
iBioPharma's common stock. However, any holder of the Company's stock who sells
shares of the Company's stock after the Record Date but before the date NASDAQ
sets as the "ex distribution" date, which we expect will be the next business
day after the Distribution Date or a few days thereafter, depending on when a
market for iBioPharma develops, will also be selling his, her or its entitlement
to receive shares of iBioPharma common stock in the Spin-Off, pursuant to what
is referred to by NASDAQ as a "due bill." Investors are encouraged to consult
with their financial advisors regarding the specific implications of selling the
Company stock before the Distribution Date or the "ex distribution" date.

The Company has changed its Record Date to allow its professional consultants to
complete the customary documents and filings associated with a spin-off
transaction.

iBioPharma has developed a novel, proprietary platform technology for the rapid,
efficient and economical manufacture of biopharmaceuticals, including vaccine
antigens, antibodies and other therapeutic proteins. iBioPharma has established
an exclusive commercial relationship with the Fraunhofer USA Center for
Molecular Biotechnology and the lead product candidates from the joint program
include influenza vaccines and an antiviral therapeutic for treatment of
influenza. Further information is available at www.ibiopharma.com

About Integrated BioPharma, Inc. (INBP)

Integrated BioPharma is a unique grouping of companies presently serving the
varied needs of the health care industry. Through its core nutraceutical
business, the Company creates, develops, manufactures and markets products
worldwide. Through its subsidiary, AgroLabs, Inc., INBP distributes and markets
healthful nutritional products under the following brands: Naturally Aloe,
Naturally Noni, Naturally Pomegranate, Naturally Thai Mangosteen and most
recently, Naturally Superberry Upgrade and among various other nutritional
products. Additionally, through its subsidiary, InB:Manhattan Drug Company, INBP
manufactures vitamins and nutritional supplements for sale to distributors,
multilevel marketers and specialized health-care providers. Its pharmaceutical
business operates a cGMP facility for the production and sale of Paclitaxel and
related drugs and provides technical services through its contract research
organization. Further information is available at www.ibiopharma.com

Statements included in this release related to Integrated BioPharma, Inc. may
constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements involve a number of
risks and uncertainties such as competitive factors, technological development,
market demand, and the Company's ability to obtain new contracts and accurately
estimate net revenues due to variability in size, scope and duration of
projects. Further information on potential risk factors that could affect the
Company's financial results can be found in the company's Reports filed with the
Securities and Exchange Commission.

-0-
CONTACT: Integrated BioPharma, Inc.
Dina Masi, CFO
Jeffrey Leach, Investor Relations
888.319.6962
j.leach@ibiopharma.com